WAVE Life Sciences Ltd
NASDAQ:WVE

Watchlist Manager
WAVE Life Sciences Ltd Logo
WAVE Life Sciences Ltd
NASDAQ:WVE
Watchlist
Price: 20.23 USD -5.07% Market Closed
Market Cap: 3.2B USD

WAVE Life Sciences Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

WAVE Life Sciences Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
WAVE Life Sciences Ltd
NASDAQ:WVE
Revenue
$109.2m
CAGR 3-Years
197%
CAGR 5-Years
53%
CAGR 10-Years
92%
Haw Par Corporation Ltd
SGX:H02
Revenue
S$253m
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
4%
H
Hyphens Pharma International Ltd
SGX:1J5
Revenue
S$185.3m
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
N/A
I
IX Biopharma Ltd
SGX:42C
Revenue
S$7.8m
CAGR 3-Years
-19%
CAGR 5-Years
51%
CAGR 10-Years
N/A
No Stocks Found

WAVE Life Sciences Ltd
Glance View

Market Cap
3.2B USD
Industry
Pharmaceuticals

WAVE Life Sciences Ltd. is a biotechnology company that sprawls across the intricate landscape of genetic medicine, focusing tirelessly on harnessing the therapeutic potential of stereochemistry in designing drugs. Founded with an innovative spirit, the company has carved out a niche by developing stereopure oligonucleotides, which are synthetically crafted RNA or DNA molecules tailored to enhance therapeutic efficacy and safety. The precision and clarity with which WAVE defines each aspect of its drug candidates separate them from many competitors in the gene therapy arena. With their proprietary platform, PRISM, WAVE leverages a deep understanding of genetic and molecular nuances to address rare genetic diseases. Their pipeline is reflective of this targeted approach, with clinical trials and research focusing on conditions like Huntington's disease, Duchenne Muscular Dystrophy, and other inherited disorders that have limited treatment options. The business model of WAVE revolves around both in-house development and strategic partnerships, driving revenue through research collaborations and potential milestone payments. By collaborating with larger pharmaceutical entities, WAVE amplifies its reach and resources, allowing it to tackle more complex challenges in genetic diseases. These partnerships are financially synergistic, enabling WAVE to continuously invest in its R&D efforts, which are pivotal for long-term growth and sustainability. The company’s focus on innovative medicines and the establishment of credible partnerships underscores its dual strategy of creating breakthrough treatments while maintaining a robust financial backbone, striving to transform the landscape of genetic therapies ethically and effectively.

WVE Intrinsic Value
HIDDEN
Show

See Also

What is WAVE Life Sciences Ltd's Revenue?
Revenue
109.2m USD

Based on the financial report for Sep 30, 2025, WAVE Life Sciences Ltd's Revenue amounts to 109.2m USD.

What is WAVE Life Sciences Ltd's Revenue growth rate?
Revenue CAGR 10Y
92%

Over the last year, the Revenue growth was 104%. The average annual Revenue growth rates for WAVE Life Sciences Ltd have been 197% over the past three years , 53% over the past five years , and 92% over the past ten years .

Back to Top